<?xml version="1.0" encoding="UTF-8"?>
<p>CP or H‐IG treatments have demonstrated clinical benefits in previous coronavirus epidemics. In severe acute respiratory syndrome (SARS), caused by SARS‐coronavirus (CoV), highly homologous to SARS‐CoV‐2, CP or H‐IG reduced mortality and hospital stay.
 <xref rid="cts12816-bib-0002" ref-type="ref">
  <sup>2</sup>
 </xref> In a meta‐analysis involving 32 studies of SARS or severe influenza, passive immunotherapy lowers mortality, especially if administered early in disease (within 5 days of symptoms). Yet, these studies often lacked control groups or had high risk of bias.
 <xref rid="cts12816-bib-0003" ref-type="ref">
  <sup>3</sup>
 </xref>
</p>
